New Delhi: IMA today released dengue guidelines and said not to panic. The present serotype is less fatal than the one whish was in 2013.
Addressing a press meet here Dr K K Aggarwal, Padma Shri Awardee and Honorary secretary General IMA said that only suspected severe dengue cases needs medical attention and admission. Most can be managed as OPD care. IMA said NO to platelet transfusion unless patient has active bleed and count less than 10,000.
Platelets counts by machine readings are bot reliable and can have an error of upto 40,000.
The reliable test is haematocrit and not platelet count. Most cases can be manages without testing by only measuring difference between upper and lower blood pressure. The pulse pressure should be kept over 40 mm Hg.
IMA also appealed to the public not to panic and do not force doctors to admit you unless it is important.
“ do bot fill beds with patients not requiring admission. Make beds available for sever dengue cases” added Dr Aggarwal.
Co-addressing the press Dr V K Monga and Dr R N Tandon from IMA said that most dengue patients can be managed with oral fluids.
New serotype of dengue
· Dengue normally is Den1, Den2, Den 3 and Den4 serotypes.
· 1 and 3 serotypes are less dangerous as compared to 2 and 4 serotypes.
· This year its 2 and 4 serotypes which are prevalent.
· As per AIIMS the type 4 strain of the disease has emerged as the dominant type for the first time in the capital, along with dengue type 2
· Symptoms of type 4 dengue include fever with shock and a drop in platelets, type 2 causes a severe drop in platelets, haemorrhagic fever, organ failure and dengue shock syndrome.
· Every strain carries the risks of hemorrhagic fever, but type 4 is less virulent than type 2. Risk of severe dengue is highest with dengue-2 viruses.
· Barring stray cases in 2003, the type 4 strain of the virus has never been isolated in Delhi
· Doctors were expecting the strain to change this year, given the large number of cases. Doctors were not expecting type 4 because it has never been actively circulating in Delhi.
· When the dominant strain remains the same for a long period, a significant population develops immunity to it, and fewer patients are diagnosed with the virus. However the type 4 strain had never even shown a significant presence. A new serotype will always end up with an epidemic like situations
· Infection with one of the four serotypes of dengue virus (primary infection) provides lifelong immunity to infection with a virus of the same serotype. However, immunity to the other dengue serotypes is transient, and individuals can subsequently be infected with another dengue serotype (secondary infection). Subsequent infection with a second type increases the likelihood of serious illness.
· The risk for severe dengue appears to decline with age, especially after age 11 years.
· AIIMS lab is also suspecting a new serotype this year in addition. Is it Den 5 ?. Researchers screening dengue viral samples found a virus collected during an outbreak in Malaysia’s Sarawak state in 2007 that they suspected was different from the four original serotypes. They sequenced the virus and found that it is phylogenetically distinct from the other four types. Experiments found that monkey antibodies produced against the new type differ significantly from those resulting from the previously known dengue viruses. So far, dengue 5 has been linked to only one outbreak in humans.
· In 1996, when an outbreak of the disease was reported in Delhi with over 10,000 cases, the relatively severe type 2 strain of the virus was identified as the most common one.
· In 2003, when a sharp rise in dengue cases was again reported, type 3, a mild strain, emerged as the most common type.
· In 2013, with over 5,500 cases, type 2 returned as the common strain in the capital.
Most dengue patients are not serious
· Dengue is both preventable and manageable
· The risk of complications is in less than one per cent of dengue cases and, if warning signals are known to the public, all deaths from dengue can be avoided.
· A platelet transfusion is not needed unless patient has active bleeding (other than petechiae ) and platelet counts are less than 10,000.
· Unnecessary platelet transfusion can cause more harm than good.
· Classic dengue fever is an acute febrile illness accompanied by headache, retro orbital pain, and marked muscle and joint pains. Symptoms typically develop between four and seven days after the bite of an infected mosquito. The incubation period may range from three to 14 days. Fever typically lasts for five to seven days. The febrile period may also be followed by a period of marked fatigue that can last for days to weeks, especially in adults. Joint pain, body aches, and rash are more common in females.
· Most complications of dengue occur after the fever is over. The two days after the last episode of the fever are crucial and during this period, a patient should be encouraged to take plenty of oral fluids mixed with salt and sugar.
· The main complication is leakage of capillaries and collection of blood outside the blood channels leading to intravascular dehydration. Giving fluids orally or by intravenous routes, if given at a proper time, can save fatal complications
Only these needs admission
“Warning signs” – World Health Organization (WHO) guidelines recommend attention to clinical warning signs for severe dengue
Severe abdominal pain or tenderness
Persistent vomiting, lethargy or restlessness
Abrupt change from fever to hypothermia
Cold /clammy extremities
Liver enlargement on physical exam
Abnormal mental status
· Dramatic plasma leakage often develop suddenly; therefore, substantial attention has been placed on early identification of patients at higher risk for shock and other complications.
· The period of maximum risk for shock is between the third and seventh day of illness. This tends to coincide with resolution of fever. Plasma leakage generally first becomes evident between 24 hours before and 24 hours after defervescence.
· An elevation of the hematocrit is an indication that plasma leakage has already occurred and that fluid repletion is urgently required.
· Low platelet count usually precedes overt plasma leakage.
· Mild elevations in serum SGOT and SGPT levels are common. Bit in severe dengue the levels are very high with SGOT > SGPT levels
· A normal SGOT levels is a strong negative predictor of severe dengue even in the first three days of illness
· NS 1 of >600 ng/mL suggests severe dengue
· Coexisting medical conditions, such as pregnancy, infancy, old age, obesity, diabetes mellitus, renal failure, and chronic hemolytic disease may increase the risk of severe dengue and/or complicate management. Referral for hospitalization is recommended for such patients, regardless of other findings
· Additionally, hospitalization should be considered for patients who may have difficulties with outpatient follow-up or with timely self-referral should complications develop (eg, patients who live alone or who live far from a healthcare facility without a reliable means of transport).
· Patients with suspected dengue who do not have any of the above indicators probably can be safely managed as outpatients, as long as close clinical observation is assured. Daily outpatient visits may be needed to permit serial assessment of blood pressure, hematocrit, and platelet count.
Government may clarify: is it an epidemic
1. Recent government circulars say: Postpone routine surgeries to accommodate dengue patients/ Postpone routine admissions/ Make provision of extra beds/ Do not refuse any patient who needs admission
2. These all are done when an epidemic is announced
3. Ina n epidemic all cases are presumed to be dengue, no confirmatory testing are done, a triage announcement is done, clear cut directions are announce regarding which patients are to be admitted and which patients re not to be admitted’
Management of significant bleeding
— Gastrointestinal bleeding, epistaxis, or menorrhagia in patients with severe dengue (and occasionally in patients with dengue fever) can be severe enough to require blood transfusion.
— Blood replacement should be performed with 5 mL/kg of packed red blood cells (or 10 mL/kg whole blood).
— Platelet transfusions have not been shown to be effective at preventing or controlling hemorrhage but may be warranted in patients with severe thrombocytopenia (<10,000/mm3) and active bleeding.
— Prophylactic platelet transfusions in patients with severe thrombocytopenia but without active bleeding are not recommended
1. 20 ml/kg body weight as bolus
2. 10 mL/kg over the next first hour
3. 7 mL/kg/hour for next two hours
4. 5 mL/kg/hour for next four hours
5. 3 mL/kg/hour for next 8 hours
Must pass urine every three hours
Duration of extra fluids
The fluids that are lost into potential spaces (eg, pleura, peritoneum) during the period of plasma leakage are rapidly reabsorbed.
Intravenous fluid supplementation should be discontinued once patients have passed the period of plasma leakage. Usually no more than 48 hours of intravenous fluid therapy are required. Excessive fluid administration after this point can precipitate hypervolemia and pulmonary edema
When to discharge
— In the absence of complications from prolonged hypotension or from medical interventions, most patients with severe dengue recover within a few days of admission
— No fever for at least 24 hours
— Two days have passed after an episode of shock
— Patient is clinically well
— Normal normal appetite, urine output, and hematocrit.
Patients with dengue should be cautioned to maintain their fluid intake to avoid dehydration and to take paracetamol as needed for fevers and myalgias. Aspirin or nonsteroidal antiinflammatory agents should generally be avoided.
Your email address will not be published. Required fields are marked *
Notify me of follow-up comments by email.
Notify me of new posts by email.
Sign me up for the newsletter!
Sixth Edition Of Jaipur BookMark To Host Global Publishers And Literary Stalwarts
Czech Pm Inaugurates Technicoat Plant In Pune
GeoAmps Provides Software Solutions For Management Of Land Rights & Infrastructure
16 Luminaries From Pune Honoured At ‘Legacies : The Changemakers’
AdvantEdge Founders Fund II – A Rs 300 Cr Mobility First Transformation Fund
2014 The Global Indian New Network (TGINN)